Metavention, Inc.

Metavention, Inc. is a medical technology company focused on innovative treatments for high blood pressure and metabolic diseases through minimally invasive procedures. Founded in 2012 and headquartered in Eden Prairie, US, Metavention, Inc. specializes in medical interventions for hypertension.

The company has undergone significant developments, including a Series C funding round in December 2017, raising USD 65 mn led by New Enterprise Associates along with participation from other notable investors. Todd Berg leads the company as CEO. Metavention specializes in innovative medical treatments aimed at addressing high blood pressure and associated metabolic diseases. The company's flagship product, the iRF Denervation System, utilizes renal denervation (RDN), a one-time, minimally invasive procedure delivering radio frequency energy to overactive sympathetic nerves tied to kidney function.

This procedure generates heat to disrupt these nerves, which can lead to reduced blood pressure and improved metabolic health outcomes. Metavention targets healthcare providers and patients globally, focusing on regions where high blood pressure is prevalent and where there is a demand for advanced therapeutic options. Their clinical studies are designed to evaluate the safety and efficacy of their treatment, positioning them as a leader in the evolving landscape of metabolic disease management. Revenue generation for Metavention primarily arises from clinical partnerships and investigations involving its iRF Denervation System.

The company engages in B2B transactions by collaborating with healthcare institutions and clinical trial sites that facilitate the administration of their innovative treatment. These partnerships allow Metavention to supply its advanced medical technology to specialized health providers who can integrate the system into their treatment protocols. The revenue structure includes fees associated with the use of the iRF Denervation System during clinical trials, along with potential future revenue from retail distributors once the product gains regulatory approval. The company's focus on patient-centered outcomes ensures that their revenue model aligns with addressing significant health challenges in hypertension management.

Metavention plans to leverage the USD 65 mn raised during its Series C funding round in December 2017 to expand its product offerings and market reach. The company is developing new therapeutic solutions targeting high blood pressure, with plans to penetrate international markets by 2025, particularly in regions with high prevalence of hypertension. The recent funding will support the acceleration of clinical trials and the regulatory approval processes to facilitate these expansions.